FDA grant Breakthrough Designation Therapy status for plinabulin for chemotherapy-induced neutropenia

Breakthrough designation for this differentiated immune and stem cell modulator was granted based on positive data from an interim analysis of the PROTECTIVE-2 Phase 3 study showing that plinabulin plus pegfilgrastim was superior to pegfilgrastim alone.


Biospace Inc.